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Abstract Sendai virus (SeV) renders cells unresponsive to
interferon (IFN)-K. To identify viral factors involved in this
process, we examined whether recombinant SeVs, which could
not express V protein, subsets of C proteins (C, CP, Y1 and Y2)
or any of four C proteins, retained the capability of impeding
IFN-K-mediated responses. Among these viruses, only the 4C
knockout virus completely lost the ability to suppress the
induction of IFN-K-stimulated gene products and the subsequent
establishment of an anti-viral state. These findings reveal crucial
roles of the SeV C proteins in blocking IFN-K-mediated
responses.
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1. Introduction
Interferons (IFNs) play important roles in early steps of
host defense mechanisms and exert their biological e¡ects
through induction of IFN-stimulated gene (ISG) products in-
cluding anti-viral proteins such as double-stranded RNA
(dsRNA) dependent protein kinase (PKR) and 2P,5P-oligoade-
nylate synthetase (2-5AS) [1]. Binding of IFN-K/L to the cell
surface receptors initiates activation of the receptor-associated
tyrosine kinases, Jak1 and Tyk2. These activated kinases
phosphorylate speci¢c tyrosine residues of signal transducers
and activators of transcription, Stat1 and Stat2, which then
combine to p48 and migrate to the nucleus to function as
active ISG factor 3 (ISGF3) [2,3]. ISGF3 binds to the IFN-
stimulated response element (ISRE) in target genes and acti-
vates transcription of ISGs [4].
A variety of viruses have developed sophisticated strategies
to counteract IFN-mediated induction of anti-viral states [5].
For example, adenovirus [6] and Epstein-Barr virus [7,8] pre-
vent activation of PKR by producing abundant small RNA
molecules that can bind to the dsRNA-binding site of PKR,
whereas vaccinia virus and reovirus express dsRNA-binding
proteins to prevent dsRNA from activating PKR [9^12]. In
contrast to mechanisms directed to the anti-viral proteins,
several viruses developed more ingenious strategies in which
the IFN signal transduction is prevented [13]. The strategies
could theoretically lead to suppression of all (more than 50)
ISG products. Poxviruses including vaccinia virus and myxo-
ma virus encode soluble IFN receptor homologues [14^18].
Adenovirus inhibits formation of ISGF3 by decreasing p48
[19,20], while human cytomegalovirus decreases Jak1 as well
as p48, two essential components of the IFN-K signaling path-
way [21]. Little is known, however, about whether these strat-
egies are common among viruses.
We have recently found that Sendai virus (SeV), a proto-
type paramyxovirus, also has the ability to suppress the anti-
viral action of IFN-K [22]. SeV is likely to be one of the
viruses evolving the ingenious strategies, since the activation
of an IFN-K/L-responsive promoter was inhibited in the SeV-
infected cells [23]. Thus, we expected that detailed analysis of
the suppression mechanism of SeV would elucidate a novel
viral strategy directed to the IFN signal transduction. In this
study, we especially focussed on viral factors responsible for
the suppression mechanism. This mechanism was very unique
and required neither viral genome replication nor secondary
transcription [22]. In fact, Sendai virions inactivated by short-
term UV-irradiation retained the ability to interfere with the
IFN-mediated induction of an anti-viral state [22]. Thus, we
speculated that responsible viral factors were encoded by the
3P upstream region of the SeV genome such as the N or P/C
gene (Fig. 1A). On the other hand, recent studies using gene
knockout SeVs, which were created by technology of the re-
verse genetics [24,25], have demonstrated that the C and V
proteins play crucial roles in in vivo growth and viral patho-
genicity [26^30]. These ¢ndings prompted us to examine
whether the C and V knockout SeVs retained the ability to
impede IFN-mediated responses.
In addition to the previously generated V(3), C/CP(3) and
4C(3) viruses, which were unable to express the V, C plus CP
and any of four C (C, CP, Y1 and Y2) proteins, respectively,
we used newly created recombinant CP(3) virus, which does
not express CP protein, in this study. We show here that
among these viruses, only the 4C(3) virus completely loses
the ability to prevent induction of ISG products as well as
the establishment of an anti-viral state.
2. Materials and methods
2.1. Generation of recombinant SeV
Generation of 4C(3), C/CP(3) and V(3) viruses was described
previously [27,29]. The CP(3) virus was newly generated essentially
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as previously described [25,29]. The initiation codon for CP was dis-
rupted by site-directed mutagenesis (Fig. 1B). A pair of complemen-
tary primers (CP1: 18305P-CGAAGCCGcGGCTGTCTCGAC-3P1809
and CP2: 18095P-GTCGAGACAGCCgCGGCTTCG-3P1830), which
contain a mutation (shown by lower-case letters) in the initiation
codon for CP, and outer primers (OP1: 615P-CAAAGTATCCACCCT-
GAGGAGCAGGTTCCAGACCCTTTGCTTTGC-3P105 and OP2:
24685P-TTACTCTTGCACTATGTG-3P2451) were used for generation
of the mutated DNA fragment by two-step PCR-based overlap primer
extension [31]. Nucleotides of primers were numbered according to
Shioda et al. [32]. The mutated DNA fragment was digested with SphI
and SalI and inserted to the corresponding position in pSeV(+), which
can generate a full length copy of parental SeV positive sense anti-
genome, to create the mutant pSeV(+)/CP(3). Using the pSeV(+)/
CP(3), the recombinant CP(3) virus was recovered as previously de-
scribed [25,29]. Mutagenesis in the P/C gene of 4C(3), C/CP(3), CP(3)
and V(3) viruses is summarized in Fig. 1B,C.
2.2. Cell cultures and virus propagation
HeLa and Vero cells were cultured in Eagle’s minimum essential
medium (MEM) supplemented with 10% bovine serum, 10% tryptose
phosphate broth and 60 Wg/ml kanamycin. Vesicular stomatitis virus
(VSV) strain New Jersey was propagated in BHK cells. Recombinant
SeV stocks, cDNA-derived Z strain as a wild-type (WT), 4C(3),
C/CP(3), CP(3) and V(3) viruses (Fig. 1B,C) [27,29], were prepared
by harvesting culture supernatant of virus-infected Vero cells incu-
bated for 3^7 days at 32‡C in serum-free MEM in the presence of
1 Wg/ml of trypsin. Hemagglutinin titers were measured as previously
described [33].
2.3. IFN and antibodies
Recombinant human IFN-K-2a was purchased from Takeda Chem-
ical Industries (Osaka, Japan). Anti-PKR rabbit polyclonal antibody
(SC-707), anti-p48 rabbit polyclonal antibody (SC-496), anti-Stat1
mouse monoclonal antibody (SC-464) and anti-Stat2 rabbit poly-
clonal antibody (SC-476) were purchased from Santa Cruz Bio-
technology (Santa Cruz, CA, USA). Mouse neutralizing monoclonal
antibody against human IFN-K (MMHA-2) and rabbit polyclonal
antibody against human IFN-L were purchased from Cosmo Bio
(Tokyo, Japan).
2.4. Assay of virus titers
VSV was titrated by the plaque assay on BHK cells. It was critical
for this study to determine conditions under which all cells were
actually infected with each recombinant SeV. Since it was di⁄cult
to determine exact titers of 4C(3) virus by the plaque assay, an
alternative titration method, hemadsorption test, was employed for
SeV. Cells in 24 well plates were infected with sequentially diluted
SeV stock. At 20 h post-infection (pi), 1% chicken erythrocytes in
phosphate-bu¡ered saline were added to the cells. After incubation
at 4‡C for 30 min, cells were extensively washed and then ¢xed with
chilled methanol. The maximum dilution of virus stocks, at which
100% of cells adsorbed erythrocytes, was determined. For all the ex-
periments in this study, cells in 24 well plates were infected with SeV
at around a 3-fold higher concentration relative to the maximum
dilution of virus stocks or infected with VSV at a multiplicity of
infection of 10 plaque forming units/cell.
2.5. Immuno£uorescent staining
Cells propagated on round cover glasses (11 mm diameter) were
¢xed with chilled methanol and then stained by the double immuno-
£uorescent method with anti-SeV rabbit serum and anti-VSV mouse
serum. Rhodamine-labelled anti-rabbit IgG goat serum (Tago, Bur-
lingame) and FITC-labelled anti-mouse IgG goat serum (Tago, Bur-
lingame) were used as the second antibodies, respectively.
2.6. Western blotting
All steps were carried out at 0^4‡C. Cells in 24 well plates were
lysed in 25 Wl of extraction bu¡er (50 mM HEPES, pH 7.6, 300 mM
NaCl, 1% Triton X-100, 1 mM Na3VO4, 1 mM dithiothreitol, 1 mM
phenylmethylsulfonyl £uoride, 1 Wg/ml leupeptin and 2 Wg/ml pepsta-
tin) according to Lee et al. [34]. Each lysate (40 or 1 Wg protein) was
electrophoresed in 7.5 or 10% sodium dodecyl sulfate-polyacrylamide
gels [35] for analysis of ISG products (Stat1, Stat2, p48 and PKR) or
virus proteins, respectively. The proteins in the gels were electrotrans-
ferred onto nitrocellulose membranes (Bio-Rad, Richmond, CA,
USA) and probed with the speci¢c antibodies. As the second anti-
bodies, horseradish peroxidase-conjugated goat anti-rabbit or anti-
mouse antibodies (Amersham Pharmacia Biotech, UK) were used.
The proteins were detected using ECL detection reagent (Amersham
Pharmacia Biotech, UK). The protein concentration was determined
by the BCA protein assay kit (Pierce, Rockford, USA).
3. Results
The genome construct of SeV is shown in Fig. 1A. SeV has
a non-segmented negative strand RNA genome of 15 384 nu-
cleotides, which encodes the nucleocapsid protein (N), phos-
phoprotein (P), matrix protein (M), fusion protein (F), he-
magglutinin-neuraminidase protein (HN) and large protein
(L) as structural proteins. Only the P/C gene exceptionally
encodes multiple species of proteins, the V, W, X, CP, C,
Y1 and Y2 proteins besides the P protein (Fig. 1A) [36,37].
The V and W mRNAs are generated by pseudotemplated
addition of one and two G residue(s) at a speci¢c P/C gene
region (1051^1053) (Fig. 1A,C), termed RNA editing, while
the unedited exact copy of the P/C gene encodes the P protein.
Therefore, the N-terminal amino acid sequence is shared with
the P, V and W proteins (Fig. 1A). On the other hand, the C
proteins, a nested set of four proteins (CP, C, Y1 and Y2),
Fig. 1. Mutagenesis in the P/C gene for generation of 4C(3), C/
CP(3), CP(3) and V(3) viruses. (A) The genome construct of SeV
and protein species encoded by the P/C gene. The P/C gene encodes
multiple proteins, V, W, X, CP, C, Y1 and Y2. The P ORF is
shown as a dotted box, the V ORF in the 31 frame as a black box
and the C ORF (+1) as an open box. (B) Sequence around the mul-
tiple initiation codons (underlined) in P mRNA and mutagenesis for
generation of 4C(3), C/CP(3) and CP(3) viruses. Mutations were
introduced to disrupt the initiation codons (114^116, 183^185 and
201^203) or to create the termination codons (126^128, 144^146 and
185^187). (C) Sequence around the RNA editing signal (underlined)
in the genome and mutagenesis for generation of V(3) virus.
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initiated at di¡erent initiation codons, are encoded by an open
reading frame (ORF) overlapping the P ORF in the +1 frame
(Fig. 1A). The V(3), CP(3), C/CP(3) and 4C(3) viruses,
which are unable to express the V, CP, C plus CP and four
C proteins, respectively, were generated as described in Sec-
tion 2.
3.1. Loss of the ability of 4C(3) virus to impede the anti-viral
action of IFN-K/L
VSV, one of the highly IFN-K/L-sensitive viruses, is used to
assess whether an anti-viral state is established by IFN-K/L or
not. First, we examined the ability of V(3) and 4C(3) viruses
to rescue of VSV replication. HeLa cells were mock-infected
or infected with WT, 4C(3) or V(3) virus and then treated
with IFN-K (1000 IU/ml) at 1 h pi. Sixteen h after SeV in-
fection, the cells were superinfected with VSV and further
incubated for 6 h. Then, the cells were ¢xed and stained dou-
bly by anti-VSV and anti-SeV antibodies. As shown in Fig. 2,
VSV antigens were detected in most cells pre-infected with
WT virus despite treatment with IFN-K (Fig. 2b,f) as de-
scribed previously [22]. On the other hand, most of the
4C(3) virus-infected cells exhibited very little or no VSV £u-
orescence irrespective of treatment with exogenous IFN-K
(Fig. 2c,g). In cells infected with V(3) virus (Fig. 2d,h), results
were similar to those obtained in the WT virus-infected cells
(Fig. 2b,f), although the ratio of cells with apparent VSV
£uorescence to those with little £uorescence seemed to be low-
er than that in the WT virus infection on the whole. The
absence of VSV antigens in the 4C(3) virus-infected cells
was not due to failure of SeV infection since the double stain-
ing method con¢rmed that all cells were certainly infected
with 4C(3) virus (data not shown). These results showed
that V(3) virus retained the ability to block the IFN-mediated
induction of an anti-viral state comparable to that of WT
virus (Fig. 2b,d,f,h), suggesting that the V protein is not in-
volved in this anti-IFN mechanism. On the other hand, 4C(3)
virus appeared to lose the anti-IFN ability completely. It was,
however, not clear why 4C(3) virus-infected cells did not
allow for VSV replication even in the absence of IFN-K. We
speculated that autocrine IFN-K/L induced by the SeV infec-
tion established an anti-viral state in the 4C(3) virus-infected
cells because of the loss of the anti-IFN ability of 4C(3) virus.
In fact, it is known that both IFN-K and IFN-L mRNAs are
induced in HeLa cells in response to virus infection [38].
To check this, we examined e¡ects of anti-IFN-K/L anti-
bodies added to the medium on rescue of VSV replication.
Fig. 3A showed Western blotting analysis of VSV proteins in
infected cells in the presence or absence of anti-IFN-K/L anti-
Fig. 2. Ability of WT, 4C(3) virus and V(3) viruses to rescue replication of VSV from the anti-viral action of IFN-K. HeLa cells were mock-
infected (Mock) or infected with each recombinant SeV. One h after infection, the media were replaced with fresh media containing IFN-K
(1000 IU/ml) or no IFN-K. Following incubation for 15 h, cells were superinfected with VSV. After further incubation for 6 h, cells were ¢xed
with chilled methanol and stained by the double immuno£uorescent method as described in Section 2. Only VSV £uorescence was shown.
Fig. 3. Ability of WT, 4C(3) and V(3) viruses to suppress the anti-
viral action of exogenous IFN-K and autocrine IFN-K/L. HeLa cells
were mock-infected (Mock) or infected with each SeV. Two h after
infection, the culture media were replaced with fresh media contain-
ing IFN-K (1000 IU/ml) (lanes 2, 5, 8 and 11) or no IFN-K (lanes
1, 4, 7 and 10). After incubation for 18 h, the cells were superin-
fected with VSV. Then, the cells were harvested at 6 h pi with VSV.
The total cell extracts were subjected to Western blotting analysis
with anti-VSV (A) or anti-SeV (B) serum. When cells were treated
with anti-IFN-K/L antibodies (lanes 3, 6, 9 and 12), the culture me-
dia contained both neutralizing mouse monoclonal anti-IFN-K (¢nal
concentration 40 Wg/ml) and rabbit polyclonal anti-IFN-L (¢nal con-
centration 3000 U/ml) throughout the experiments.
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bodies or exogenous IFN-K. Exogenously added IFN-K com-
pletely inhibited production of all viral components of VSV in
HeLa cells (Fig. 3A, lane 2), while infection with WT or V(3)
virus allowed for VSV protein synthesis (Fig. 3A, lanes 5 and
11). In the 4C(3) virus-infected cells, however, no accumula-
tion of VSV proteins was observed irrespective of IFN-K
treatment (Fig. 3A, lanes 7 and 8). These results were in
good agreement with those in the immuno£uorescent experi-
ment described above.
Anti-IFN-K/L antibodies treatment did not a¡ect notably
VSV protein synthesis in WT or V(3) virus-infected cells
(Fig. 3A, lanes 6 and 12). In contrast, the accumulation of
VSV antigens was dramatically enhanced in the 4C(3)-in-
fected cells (Fig. 3A, lane 9), indicating that autocrine IFN-
K/L at least in part contributed to suppression of VSV protein
synthesis in the 4C(3) virus-infected cells without exogenous
IFN-K. We also examined SeV protein synthesis in the in-
fected cells. Accumulation of the 4C(3) virus proteins was
found to be less than that of WT or V(3) virus proteins
(Fig. 3B, lanes 4, 7 and 10). Neither anti-IFN-K/L antibodies
nor exogenous IFN-K a¡ected WT and V(3) virus protein
syntheses (Fig. 3B, lanes 6 and 12), while the 4C(3) virus
protein synthesis was found to be suppressed or recovered
to some extent by IFN-K treatment or by anti-IFN-K/L anti-
bodies treatment, respectively (Fig. 3B, lanes 8 and 9). These
results demonstrated that SeV protein synthesis was actually
in£uenced by autocrine IFN-K/L in the absence of the SeV C
proteins.
3.2. Complete loss of the ability of 4C(3) virus to suppress
induction of ISG products
As described above, an anti-viral state was induced in the
4C(3) virus-infected cells, but not in the WT and V(3) virus-
infected cells. To see this di¡erence at a level of host cell gene
expression, we examined the ability of each virus to impede
induction of ISG products. Stat1, Stat2 and p48, components
of ISGF3, were chosen for the ISG products [39] besides
PKR. HeLa cells were mock-infected or infected with each
SeV and treated or untreated with IFN-K at 2 h pi. Cells
were harvested 18 h after IFN-K treatment. Fig. 4 showed
that IFN-K treatment remarkably increased Stat1 (Stat1K
and Stat1L) and p48, in the 4C(3) virus-infected cells (Fig.
4, lane 11) comparable with those in mock-infected cells (Fig.
4, lane 3), whereas in the WT or V(3) virus-infected cells,
induction of Stat1 and p48 by autocrine IFN-K/L or exoge-
nous IFN-K was strikingly suppressed (Fig. 4, lanes 6, 7, 14
and 15). As expected, even in the absence of exogenous IFN-
K, Stat1 and p48 were markedly induced in the 4C(3) virus-
infected cells (Fig. 4, lane 10). On the other hand, anti-IFN-K/
L antibodies suppressed increase of these ISG products in the
4C(3)-infected cells (Fig. 4, lane 12), con¢rming that auto-
crine IFN-K/L actually acted to establish the anti-viral state
on the 4C(3) virus-infected cells. Similar results were ob-
tained in the induction of Stat2 and PKR (data not shown).
These results, consistent with those observed in Fig. 3, sug-
gested that the 4C(3) virus allowed for the establishment of
an anti-viral state in the infected cells by the complete loss of
the ability to prevent induction of ISG products.
3.3. Ability of C/CP(3) and CP(3) viruses to suppress
induction of ISG products
The ability of C/CP(3) and CP(3) viruses to suppress in-
duction of ISG products was also examined. In the C/CP(3)
virus-infected cells, Stat1 and p48 were induced to some extent
probably by autocrine IFN-K/L in the absence of exogenous
IFN-K (Fig. 5 lane 4), but the level of the induction was
inferior to that in the 4C(3) virus-infected cells (Fig. 5 lane
3). Induction of Stat1 and p48 was strongly suppressed in the
CP(3) virus-infected cells (Fig. 5, lane 5). When cells were
treated with exogenous IFN-K, the di¡erence between the
4C(3) and the other viruses became more evident. Induction
of Stat1 and p48 in the C/CP(3) virus-infected cells was found
to be suppressed considerably compared with that in the
4C(3) virus-infected cells. The suppression by CP(3) virus
appeared to be stronger than that of WT virus. Similar results
were obtained in the induction of Stat2 and PKR (data not
shown). The Y1 and Y2 proteins were overexpressed in HeLa
cells infected with C/CP(3) virus (data not shown) as previ-
ously described [29]. Therefore, overexpressed Y1 and Y2
proteins largely compensated for the loss of functions of the
C and CP proteins and could contribute to suppression of
induction of the ISG products to some extent.
4. Discussion
The present study demonstrated that both WT and V(3)
Fig. 4. Ability of WT, 4C(3) and V(3) viruses to suppress induc-
tion of Stat1K,L and p48. HeLa cells were mock-infected (Mock) or
infected with each SeV. The culture media were replaced at 2 h pi
with fresh media containing IFN-K (1000 IU/ml) (lanes 3, 7, 11 and
15) or no IFN-K (lanes 1, 2, 5, 6, 9, 10, 13 and 14). The cells were
further incubated for 18 h until cell harvesting. When cells were
treated with anti-IFN-K/L antibodies, the treatment conditions were
the same as those in Fig. 3. The total cell lysates were analyzed by
Western blotting with anti-Stat1 and anti-p48 antibodies.
Fig. 5. Ability of C/CP(3) and CP(3) viruses to suppress induction
of Stat1 and p48. HeLa cells were mock-infected (Mock) or infected
with each virus. The media were replaced at 2 h pi with fresh media
containing IFN-K (1000 IU/ml) (lanes 6^10) or no IFN-K (lanes 1^
5). The cells were harvested after a further 18 h incubation. The to-
tal cell lysates were analyzed by Western blotting with anti-Stat1
and anti-p48 antibodies.
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viruses blocked the induction of ISG products (Stat1, p48,
Stat2 and PKR) and consequently prevented the establish-
ment of an anti-viral state. Didcock et al. reported that trans-
fection of a plasmid carrying a synthetic promoter containing
multimers of the well-de¢ned ISRE linked to the luciferase
reporter gene did not respond to IFN-K/L in cells infected
with SeV [23]. They further showed that induction of the
IFN-responsive 6-16 gene was inhibited by SeV infection. To-
gether with their results, our ¢ndings support the idea that
SeV interferes with the IFN-K/L signal transduction.
In contrast to WT and V(3) viruses, the 4C(3) virus com-
pletely lost the ability to suppress the IFN-mediated re-
sponses, demonstrating that the C proteins play crucial roles
in preventing IFN-mediated induction of an anti-viral state. It
is unlikely that a low accumulation of SeV proteins in infected
cells (Fig. 3B, lane7) is responsible for loss of the anti-IFN
ability of 4C(3) virus, because even replication-incompetent
SeV can suppress the IFN-K/L-mediated anti-viral responses
[22]. Rather, previous double immunostaining experiments
showed that detectable levels of viral proteins were not re-
quired for the anti-IFN ability [22]. Recently, Garcin et al.
have reached essentially the same conclusion using mutant
viruses containing a single amino acid substitution in the C
protein and similar recombinant viruses which do not express
subsets of the C proteins [40]. They concluded that the
AUG114-initiated C protein prevents the establishment of an
anti-viral state, from the results showing that not only the
double mutant corresponding to the C/CP(3) virus but also
the C(3) mutant allowed for IFN-K/L-mediated induction of
Stat1 and lost the ability to rescue VSV. We, however, found
that C/CP(3) virus retained the considerable ability to sup-
press the ISG products, although the suppression is slightly
weak compared with WT and CP(3) viruses (Fig. 5). There-
fore, our results suggest that Y1 and Y2 proteins can also play
a critical role in prevention of the IFN-mediated responses.
Although the reasons for the discrepancies between our and
their results are unknown, they might be due to a di¡erence in
cell lines used or experimental conditions.
Growth of 4C(3) virus in ovo was very poor and was
reduced by several logs, compared with that of WT virus
[29]. Even CCP(3) virus was almost totally incapable of rep-
licating in the mouse lung [29]. Therefore, 4C(3) virus is likely
to be more avirulent than CCP(3) virus. This possible attenu-
ation as well as poor growth of 4C(3) virus in ovo is explain-
able in part by loss of the ability of 4C(3) virus to prevent
autocrine IFN-K/L from inducing an anti-viral state, as shown
in our in vitro study presented here. Although SeV protein
synthesis was actually suppressed by autocrine IFN-K/L in the
4C(3) virus-infected HeLa cells (Fig. 3B), its extent was not
so striking when compared with the inhibition of VSV protein
synthesis (Fig. 3A). This di¡erence is probably due to the
timing of the action of IFN-K/L. In the experiments shown
in Fig. 3A, VSV infection followed establishment of the anti-
viral state (Fig. 4), while SeV infection preceded it. Thus, the
timing of virus infection to IFN treatment is an important
factor for blocking IFN-mediated responses. We con¢rmed
that SeV infection could not prevent IFN-mediated responses
in cells pre-treated with IFN-K as reported by Didcock et al.
[23]. On the other hand, it is well known that SeV is a good
inducer of IFN-K/L. Therefore, it remains to be elucidated
why WT virus can spread to neighboring cells in which an
anti-viral state has already been established by the action of
paracrine IFN-K/L. Why has SeV evolved the anti-IFN strat-
egy in contrast to VSV? We previously reported that VSV
protein synthesis was not inhibited at all by IFN-L treatment,
if IFN-L was added to cells concomitantly with VSV infection
[41]. Therefore, it is unlikely that VSV growth is a¡ected by
autocrine IFN-K/L. VSV, due to its rapid growth, may not
need an anti-IFN strategy like SeV. Thus, we speculate that
SeV must have evolved the anti-IFN strategy in compensation
for its slower growth.
We observed acceleration of cytopathic e¡ects in the 4C(3)
virus-infected HeLa cells (IFN-K/L producing cells) compared
with those in the WT virus-infected cells (unpublished results),
although we did not determine whether the cytopathic e¡ects
were due to apoptosis. Therefore, the anti-IFN mechanisms
may be linked to induction of apoptosis as speculated by
Garcin et al. [40], since activation of PKR or 2-5AS induces
apoptosis [42^45]. If the ability of SeV to inhibit IFN-K/L-
mediated responses is also responsible for delay in deteriora-
tion of cell functions, it will be of advantage to the virus
growth.
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